Urolog. pro Praxi, 2008; 9(2): 61-63

Overactive bladder: cost-effectiveness of oxybutynin IR and solifenacin

MUDr. Jana Skoupá
Pharma Projects, Praha

The paper evaluates the cost-effectiveness in patients with an overactive bladder who are treated with either short-acting oxybutynin or solifenacin. In addition to medication costs, the costs also include treatments for some comorbidities such as depressions and urinary infections. The clinical outcome to which costs are related is achievement of continence.

Keywords: overactive bladder, cost efficiency, oxybutynin IR, solifenacin

Published: May 21, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skoupá J. Overactive bladder: cost-effectiveness of oxybutynin IR and solifenacin. Urol. praxi. 2008;9(2):61-63.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, et al. The standardization of terminology of lower urinary tract function: Report from the Standardization Sub-Committee of the International Society. Am J Obs Gyn. 2002; 187: 116-126. Go to original source... Go to PubMed...
    2. Abrams P, et al. The standardization of terminology of lower urinary tract function: Report from the standardization sub-committee of the International Continence Society. Urology 2003; 61(1): 37-49. Go to original source... Go to PubMed...
    3. Irwin DE, et al. SUFU 2007 - Impact of OAB and incontinence on mental health and health-related quality of life in women. www.urotoday.com. 2007.
    4. Kobelt G, et al. Quality of Life aspects of the OAB and the effect of treatment with tolterodine. BJU 1999; 83: 583-590. Go to original source... Go to PubMed...
    5. Kobelt G, Jonsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent, a Markov model. Neurourol Urodyn 1998: 17: 599-611. Go to original source... Go to PubMed...
    6. Krhut J. Praktické aspekty diagnostiky a léčby hyperaktivního měchýře. Urolog. pro Praxi 2007; 2: 71-74.
    7. Liberman JN, et al. Health-related quality of life among adults with symptoms of overactive bladder: Results form a US community-based survey. Urology 2001; 57: 1044-1050. Go to original source... Go to PubMed...
    8. McDonagh MS, et al. Drug Class Review on Agents for Overactive Bladder. Oregon Evidence-based Practice Center 2005.
    9. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001; 87: 760-766. Go to original source... Go to PubMed...
    10. Reeves, et al. The Current and Future Burden and Cost of Overactive Bladder in Five European Countries. Eur Urol. 2006; 50 (5): 1050-1057. Go to original source... Go to PubMed...
    11. Stach-Lempinen B, et al. Severe depression determines quality of life in urinary incontinent women. Neurourol Urodyn. 2003; 22: 563-568. Go to original source... Go to PubMed...
    12. Temml Ch, et al. Prevalence of the Overactive Bladder Syndrome by Applying the International Continence Society Definition. European Urology 2005; 48(4): 622-627. Go to original source... Go to PubMed...
    13. Vidlář A, et al. Farmakologická léčba hyperaktivního močového měchýře a urgentní inkontinence. Urolog. pro Praxi 2007; 8(4): 158-162.
    14. Wagner TH, et al. Health-related consequences of OAB. Am J Manag Care 2002; 8(19 Suppl): S598-S607. Go to PubMed...
    15. Zorn BH, et al. Urinary incontinence and depression. J Urol. 1999; 162: 82-84. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.